143 related articles for article (PubMed ID: 22483786)
1. An "I" on cardiac hypertrophic remodelling: imidazoline receptors and heart disease.
Mukaddam-Daher S
Can J Cardiol; 2012; 28(5):590-8. PubMed ID: 22483786
[TBL] [Abstract][Full Text] [Related]
2. Moxonidine modulates cytokine signalling and effects on cardiac cell viability.
Aceros H; Farah G; Noiseux N; Mukaddam-Daher S
Eur J Pharmacol; 2014 Oct; 740():168-82. PubMed ID: 25036265
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
4. Functional and molecular effects of imidazoline receptor activation in heart failure.
Stabile AM; Aceros H; Stockmeyer K; Abdel Rahman AA; Noiseux N; Mukaddam-Daher S
Life Sci; 2011 Mar; 88(11-12):493-503. PubMed ID: 21277868
[TBL] [Abstract][Full Text] [Related]
5. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.
Aceros H; Farah G; Cobos-Puc L; Stabile AM; Noiseux N; Mukaddam-Daher S
Br J Pharmacol; 2011 Oct; 164(3):946-57. PubMed ID: 21426316
[TBL] [Abstract][Full Text] [Related]
6. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice.
Zou Y; Lin L; Ye Y; Wei J; Zhou N; Liang Y; Gong H; Li L; Wu J; Li Y; Jia Z; Wu Y; Zhou J; Ge J
J Cardiovasc Pharmacol; 2012 Mar; 59(3):268-80. PubMed ID: 22075750
[TBL] [Abstract][Full Text] [Related]
7. Moxonidine: a new antiadrenergic antihypertensive agent.
Prichard BN; Graham BR; Owens CW
J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
[TBL] [Abstract][Full Text] [Related]
8. The role of bradykinin B1 receptor on cardiac remodeling in stroke-prone spontaneously hypertensive rats (SHR-SP).
Moniwa N; Agata J; Hagiwara M; Ura N; Shimamoto K
Biol Chem; 2006 Feb; 387(2):203-9. PubMed ID: 16497153
[TBL] [Abstract][Full Text] [Related]
9. Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure.
Moorjani N; Westaby S; Narula J; Catarino PA; Brittin R; Kemp TJ; Narula N; Sugden PH
Am J Cardiol; 2009 May; 103(9):1261-8. PubMed ID: 19406269
[TBL] [Abstract][Full Text] [Related]
10. Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats.
Kuo WW; Chu CY; Wu CH; Lin JA; Liu JY; Hsieh YH; Ueng KC; Lee SD; Hsieh DJ; Hsu HH; Chen LM; Huang CY
Cell Biochem Funct; 2005; 23(5):325-31. PubMed ID: 15996002
[TBL] [Abstract][Full Text] [Related]
11. Involvement of cardiomyocyte survival-apoptosis balance in hypertensive cardiac remodeling.
Fortuño MA; López N; González A; Díez J
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):293-307. PubMed ID: 15030288
[TBL] [Abstract][Full Text] [Related]
12. Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1.
Fan GC; Yuan Q; Song G; Wang Y; Chen G; Qian J; Zhou X; Lee YJ; Ashraf M; Kranias EG
Circ Res; 2006 Nov; 99(11):1233-42. PubMed ID: 17068291
[TBL] [Abstract][Full Text] [Related]
13. β1-Integrin is up-regulated via Rac1-dependent reactive oxygen species as part of the hypertrophic cardiomyocyte response.
Häuselmann SP; Rosc-Schlüter BI; Lorenz V; Plaisance I; Brink M; Pfister O; Kuster GM
Free Radic Biol Med; 2011 Aug; 51(3):609-18. PubMed ID: 21620958
[TBL] [Abstract][Full Text] [Related]
14. Imidazoline receptors but not alpha 2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment.
El-Ayoubi R; Menaouar A; Gutkowska J; Mukaddam-Daher S
J Pharmacol Exp Ther; 2004 Aug; 310(2):446-51. PubMed ID: 15075383
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
[TBL] [Abstract][Full Text] [Related]
16. Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats.
Ikeda S; Hamada M; Hiwada K
Clin Sci (Lond); 1999 Aug; 97(2):239-46. PubMed ID: 10409480
[TBL] [Abstract][Full Text] [Related]
17. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Lister K; Autelitano DJ; Jenkins A; Hannan RD; Sheppard KE
Cardiovasc Res; 2006 Jun; 70(3):555-65. PubMed ID: 16533503
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.
Takayama N; Kai H; Kudo H; Yasuoka S; Mori T; Anegawa T; Koga M; Kajimoto H; Hirooka Y; Imaizumi T
Hypertens Res; 2011 Mar; 34(3):341-7. PubMed ID: 21124329
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Dahlöf B
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
[TBL] [Abstract][Full Text] [Related]
20. Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Asanuma H; Minamino T; Tomoike H; Hori M; Kitakaze M
Cardiovasc Res; 2005 Mar; 65(4):879-88. PubMed ID: 15721868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
